Precision Peptide Company Inc

Precision Peptide Company Inc has a debt-free capital structure, with a debt-to-equity ratio of 0.0, indicating no leverage in its financing. The company's liquidity position is weak, as reflected in its low liquidity risk rating and a current ratio of 3.32, which is below the typical threshold for financial stability. The company's negative operating and free cash flows (-$2.33 million and -$4.44 million, respectively) suggest ongoing cash burn and limited ability to fund operations without external financing. The company's profitability metrics are deeply negative, with a return on equity of -4.87 and a return on assets of -3.40, both significantly below the industry median for Food Processing companies. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit. The gross profit margin of 44.2% (calculated from $21,950 revenue and $49,720 gross profit) is relatively high, but this is offset by massive operating and net losses. The company's revenue is concentrated in North America, as disclosed in its business description, but no specific geographic breakdown is provided in the financial data. The company operates in a single business segment, with no disclosed diversification across product lines or geographic regions. This lack of diversification increases exposure to regional economic downturns and regulatory changes. The company's growth trajectory is unclear, as no forward-looking revenue guidance is provided in the outlook data. Historical revenue of $49.72 million is insufficient to determine a growth pattern, and the absence of positive operating cash flow or net income suggests the company is not currently in a growth phase. The company's negative operating and free cash flows indicate a need for external capital to sustain operations, which could impact future growth initiatives. The company's risk profile is characterized by low liquidity and low dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses suggest a potential need for future capital raising, which could lead to dilution of existing shareholders. The absence of long-term debt and the low dilution risk rating indicate that the company is not currently under pressure to raise capital through equity issuance. Recent events include the company's rebranding from Pangea Wellness Inc. to Precision Peptide Company Inc., reflecting a strategic shift toward peptide-based wellness products. No recent filings or transcripts are provided in the input data to indicate further developments in the company's operations or financial strategy.